earticle

영어

Chimeric antigen receptor (CAR)-T cell therapy, a cell based gene therapy, has been covered as a condition of the performance- based refund under national health insurance system since April 2022. Accordingly, the effectiveness and adverse drug reaction of CAR-T cell therapy should be reported to the Health Insurance Review and Assessment. (HIRA). Hospital pharmacists are expected to be responsible for monitoring the CAR-T cell therapy. Thus, literature review was conducted to determine the role of hospital pharmacists in the CAR-T cell therapy. There were no related articles in searching the domestic database, and seven articles were selected from PubMED database. Most of them were review-type papers describing the role of pharmacists, and one of them developed practical guidelines for hospital pharmacies. The roles of pharmacists were summarized into nineteen categories. Critical roles include developing standard operating procedures, training staff and patients, managing T cell collection, preparing and storing CAR-T cell, and monitoring and managing adverse drug reaction. The participation of hospital pharmacists in the process of CAR-T cell therapy can improve the effectiveness and safety of patients, and the responsibilities of hospital pharmacists should be standardized within a multidisciplinary team.